Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC

/PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation,...

Related Keywords

France ,Japan ,Italy ,Germany ,United Kingdom ,South Korea ,China ,Spain ,Seongnam ,Kyonggi Do ,Republic Of Korea ,South Korean ,James Lee ,Bridge Biotherapeutics Inc ,Biotherapeutics Inc ,Recommended Dose Range ,Recommended Phase ,Response Evaluation Criteria ,Solid Tumors ,First In Human Study ,Advanced Non Small Cell Lung Cancer Harboring ,After Treatment ,Non Small Cell Lung Cancer ,Epidemiology Forecast Report ,Bridge Biotherapeutics ,Nc ,Health Care Amp Hospitals ,Biotechnology ,Medical Pharmaceuticals ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,